PI3K‐AKT‐mTOR inhibition might add to the treatment of autoimmune diseases where autoantibodies produced by B cells play a role and could complement treatment with B cell depletion or when anti‐CD20 regimens show insufficient effectiveness. This evidence concerns the gene AKT1 and autoimmune disease.